Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 4;27(1):35.
doi: 10.1007/s11894-025-00987-3.

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations

Sarah Rotondo-Trivette  1 , William Jennings  2 , David Fudman  3
Affiliations
Review

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations

Sarah Rotondo-Trivette et al. Curr Gastroenterol Rep. .

Abstract

Purpose of review: This review summarizes the literature on IL-23 inhibitors for inflammatory bowel disease and the role of these agents in clinical practice.

Recent findings: The last decade has seen several pivotal trials investigating IL-23 inhibitors. These agents are effective in inducing and maintaining remission of moderate-to-severe inflammatory bowel disease, including among those with prior biologic failure, and have low adverse events. IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn's disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences.

Keywords: Crohn’s disease; Guselkumab; Inflammatory bowel disease; Interleukin-23; Mirikizumab; Risankizumab; Ulcerative Colitis; Ustekinumab.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: Sarah Rotondo-Trivette and William Jennings have no competing interests to report. David Fudman reports advisory board fees from Pfizer, Fresenius Kabi and Janssen.

Similar articles

See all similar articles

References

    1. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309–18. - PubMed - DOI
    1. Hui GK, Gao X, Gor J, Lu J, Sun PD, Perkins SJ. The solution structure of the unbound IgG Fc receptor CD64 resembles its crystal structure: implications for function. PLoS ONE. 2023;18:e0288351. - PubMed - PMC - DOI
    1. Sachen KL, Hammaker D, Sarabia I, et al. Guselkumab binding to CD64 + IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling. Front Immunol. 2025;16:1532852. - PubMed - PMC - DOI
    1. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ. Interleukin-23 drives innate and T cell–mediated intestinal inflammation. J Exp Med. 2006;203:2473–83. - PubMed - PMC - DOI
    1. Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N, Alimentiv Translational Research Consortium (ATRC). IL-12 and IL-23 pathway Inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20:433–46. - PubMed - PMC - DOI

MeSH terms

LinkOut - more resources